Introduction Of Proton Pump Inhibitors Research Articles

Perforated Peptic Ulcer-Current Management: A Narrative Review

Perforated peptic ulcer is a complication of peptic ulcer disease with its incidence being stable despite the introduction of proton pump inhibitors. This condition is seen in older patients with comorbidities and early diagnosis improves the mortality of this condition. The treatment of perforated peptic ulcer is performed by closure of the perforated peptic ulcer, and this procedure can be performed by open or laparoscopic surgery. The current trend over the last few years has been the use of laparoscopic surgery in the management of perforated peptic ulcer and we have conducted this narrative review article to investigate the current trend in management of this condition.

Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease.

Gastroesophageal reflux disease (GERD) is associated with significant morbidity in patients with systemic sclerosis (SSc). Although the introduction of proton pump inhibitors (PPIs) into clinical care have represented a major achievement in the management of oesophago-gastric problems in SSc, PPIs are seldom fully effective in SSc patients, and the utilization of maximum PPI dosages is a very frequent clinical practice. However, currently there is little evidence currently to support the empiric use of PPIs in SSc which is especially relevant in regard to safety concerns of long-term exposure with have been raised in the general population. The purpose of this viewpoint is to highlight the significant beneficial impact of PPIs on GERD in SSc, while considering the potential adverse effects in this patient population. Furthermore, we highlight the unmet needs of SSc patients with GERD, and also propose an agenda for future research to optimise the safe and effective use of PPIs in SSc.

Rebuilding trust in proton pump inhibitor therapy.

Introduction of proton pump inhibitor (PPI) therapy into clinical practice has revolutionized treatment approach to acid-related diseases. With its clinical success came a widespread use of PPI therapy. Subsequently, several studies found that PPIs were oftentimes overprescribed in primary care and emergency setting, likely attributed to seemingly low side-effect profile and physicians having low threshold to initiate therapy. However, now there is a growing concern over PPI side-effect profile among both patients and providers. We would like to bring more awareness to the currently available guidelines on PPI use, discuss clinical indications for PPIs and the evidence behind the reported side-effects. We hope that increased awareness of proper PPI use will make the initiation or continuation of therapy a well informed and an evidence-based decision between patient and physician. We also hope that discussing evidence behind the reported side-effect profile will help clarify the growing concerns over PPI therapy.

Linking Individually Induced Electric Fields to Head Anatomy and Cognitive tES Effects

The introduction of proton pump inhibitors (PPIs) into clinical practice about thirty years ago has greatly improved our therapeutic approach to acid-related diseases for their well-recognized efficacy and safety.Despite the well-defined indications, however, the use of PPIs continues to grow every year in both western and eastern countries and this phenomenon poses serious queries that include the onset of potential adverse effects and the increase in health care costs. The major reason explaining this worrying market expansion is the inappropriate use of PPIs. In order to re-establish a correct use of these effective drugs in daily clinical practice, the Italian Society of Gastroenterology (SIGE), nominated a panel of experts who reviewed the available clinical literature and produced a series of updated position statements on the use of PPIs in clinical practice.

Peptic Ulcer Perforation: An Enigma Since Antiquity

Peptic ulcer disease (PUD) is a serious medical condition. The perforation of peptic ulcers (PPU) causes a steep rise in mortality and morbidity. It accounts for 70% of deaths associated with PUD. More than 60% of perforations occur in the anterior wall of the duodenum, while 20% of it is in the antrum. The gastric ulcer perforation contributes to approximately 20% and is in lesser curvature. The risk factor includes non-steroidal anti-inflammatory drugs (NSAID), Helicobactor pylori (H. Pylori), smoking, alcoholism, Corticosteroid, and stress are some of the risk factors. There is a change in the epidemiology of PUD recently. The improvement is remarkable and is due to improved socio-economic status, identification and treatment of Helicobacter pylori, and introduction of proton pump inhibitors. The H pylori infection remains one of the most important causes of PUD and its complications like PPU. The reason for reviewing and writing this paper is to evaluate the most common ideas on the treatment of peptic ulcer perforation, opinion on conservative treatment, and surgical treatment options.

Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.

Proton pump inhibitors (PPIs) are benzimidazole-derivative chiral sulfoxides, frequently used in the treatment of gastric hyperacidity-related disorders. Due to their stereoselective metabolism, the eutomeric forms of PPIs can present a more advantageous pharmacokinetic profile by comparison with the distomers or racemates. Moreover, two representatives of the class are used in therapy both as racemates and as pure enantiomers (esomeprazole, dexlansoprazole). A relatively large number of enantioseparation methods employed for the stereoselective determination of PPIs from pharmaceutical, biological, and environmental matrices were published in the past three decades. The purpose of the current overview is to provide a systematic survey of the available chiral separation methods published since the introduction of PPIs in the therapy up to the present. Analytical and bioanalytical methods using different chromatographic and electromigration techniques reported for the enantioseparation of omeprazole, lansoprazole, pantoprazole, rabeprazole, ilaprazole, and tenatoprazole are included. The analytical conditions of the presented methods are summarized in three comprehensive tables, while a critical discussion of the applied techniques, possible mechanism of enantiorecognition, and future perspectives on the topic are also presented.

Endoscopic changes in patients diagnosed with acute pancreatitis.

There have been long debates on the introduction of proton pump inhibitors into acute pancreatitis therapy as standard treatment. The aim of the study was to assess endoscopic lesions of the upper gastrointestinal tract in patients hospitalized for acute pancreatitis. We carried out a prospective analysis of patients hospitalized in one surgical center who had an upper gastrointestinal tract endoscopic examination performed during the first 48 hours of hospitalization. We performed analysis of basic descriptive statistics along with the Shapiro-Wilk Test, logistic order regression analysis, One-Way Analysis of Variance, and Student's t-test for independent trials. From January 2016 to December 2019, 476 patients were hospitalized because of acute pancreatitis. The upper gastrointestinal tract endoscopic examination was performed in 85 patients (N.) in the first 48 hours. From the examined group 45 patients (52.94%) developed mild acute pancreatitis, 28 (32.94%) moderate pancreatitis, and 12 (14.12%) severe pancreatitis. Lesions in the endoscopic imaging were observed in 80 patients (94.12%). A very high percentage of patients hospitalized for acute pancreatitis present lesions in the endoscopic imaging of the upper gastrointestinal tract. The standard treatment of AP is the administration of non-steroidal anti-inflammatory drugs, which themselves can cause gastric and duodenal mucosal defects. All these factors indicate the need for standard use of proton pump inhibitors in patients hospitalized for acute pancreatitis.

Proton Pump Inhibitors and Primary Liver Cancer

During the last years proton pump inhibitors (PPIs), previously regarded as very safe drugs and allowed to be sold over the counter, have been reported to give side effects in many organ systems. However, most of these negative reports probably are due to residual confounding factors. In general, the side effects of PPIs are due to their biological effect in removing the biological effect of gastric juice that is killing microorganisms, and the secondary hypergastrinemia in an unsuccessful attempt to restore normal gastric acidity. Whereas the possibility that hypergastrinemia could predispose to gastric cancer has been permanently on the agenda since the introduction of PPIs, the removal of the important protective effect towards microbes has surprisingly only been focused on during the later years as a consequence of increased interest on the gut microbiome. PPI treatment affects the microbiome, and it exists one report describing increased risk of primary liver cancer due to PPI use. Changes in the gut microbiome have been shown to participate in the pathogenesis of chronic liver diseases caused by ethanol as well as obesity. In general, chronic liver diseases predispose to liver cancer. There are also rodent studies incriminating inhibition of gastric acid secretion in the pathogenesis of primary liver cancer. However, it must be concluded that presently the role of PPIs in the development of primary liver cancer seems weak.

Completion total gastrectomy with intracorporeal robot-sewn esophago-jejunal anastomosis

Many technical reports concern minimally invasive surgery for stomach cancer; however, there is poor evidence about employing this approach for gastric stump cancer, which can arise at the anastomotic site in patients who have undergone previous partial gastrectomy for benign diseases such as gastric ulcer. Such surgery was quite common before the introduction of proton pump inhibitors (PPIs), and so today, according to different statistics, gastric stump cancer can be revealed in up to 8% of these patients. This report seeks to highlight the possibility of employing a minimally invasive approach in patients who already had an operation for gastric resection. The video shows technical notes about the hybrid laparoscopic-robotic approach performed in a patient who previously underwent open distal gastrectomy. Is the previous laparotomy an absolute or relative counterindication to reperform a surgery through a minimally invasive approach?

A clinical study of factors affecting the prognosis in duodenal ulcer perforation cases in tertiary care hospital, Kanchipuram district

Background: Peptic ulcer disease is an erosion of the lining of the stomach or duodenum. It is associated with potentially life-threatening complications such as bleeding, perforation and obstruction. The main predisposing factors for peptic ulcer perforation are smoking, use of non-steroidal anti-inflammatory drugs (NSAIDs), chronic stress, Helicobacter pylori infection, and age >60 years. In recent years, with introduction of proton pump inhibitors and increased knowledge of duodenal ulcer perforation (DUP) has decreased the incidence of DUP.Methods: 50 patients with DUP were studied prospectively with respect to age, gender, use of NSAIDs, morbidity, mortality and complications.Results: Out of 50 patients, the mean age of incidence DUP was 46 yrs, which is more common in males. And also 48% patients were chronic alcoholic and 52% patients were chronic smokers. Moreover, 14% patients were chronic NSAIDs users.Conclusions: Factors such as age, gender, use of NSAID, Alcohol and smoking affects the life expectancy of the patients, which leads to morbidity and mortality.

Eosinophilic esophagitis: pitfalls and controversies in diagnosis and management.

Formerly considered a rare disorder, eosinophilic esophagitis (EoE) has emerged as a leading cause of feeding problems in children and an increasingly recognized cause of dysphagia and food impaction in adults. Our understanding of EoE and its complex interplay with gastro-esophageal reflux disease (GERD) has evolved over the past decade and culminated in the introduction of proton pump inhibitor (PPI) responsive EoE as a distinct entity which has added to this complexity. It is now clear that this entity is on the same spectrum as the original EoE, and that PPIs should be considered as part of treatment protocol and should not be recommended as a diagnostic tool. As such, removing the PPI trial from the diagnostic algorithm has been encouraged recently. Recent guidelines and reviews thoroughly address various aspects in EoE pathogenesis and diagnostic workup as well as management endpoints, treatment options and novel therapies. However, despite the recent extensive study and the advances in our knowledge of this disease, unmet needs and pitfalls in diagnostic workup and management of these patients are still to be clarified and will be under focus in this review.

3231 Gastric Outlet Obstruction in a Patient After Hip Surgery

INTRODUCTION: Until the 1970s, peptic ulcer disease was the most prevalent cause for gastric outlet obstructions (GOO) and accounted for 90 percent of all cases. However, with the introduction of proton pump inhibitors (PPI) and the treatment of H. pylori infections, the etiology of GOO changed rapidly. Today, only around two percent of all peptic ulcers lead to GOO. Here we report the case of a woman with nausea, abdominal pain and coffee ground emesis, found to have a GOO, whose symptoms completely subsided under PPI treatment of a 12 mm large peptic ulcer (Forrest III) in the duodenal bulb. CASE DESCRIPTION/METHODS: A 62-year-old female patient with a history of hypothyroidism, recent left hip fracture repair and subsequent pulmonary embolism, presented with nausea, hematemesis, melena, epigastric pain, decreased appetite and weight loss. She was treated with daily aspirin 325 mg and apixaban, and denied any drug abuse. PPI prophylaxis was not administered. Her physical examination was unremarkable. Initial blood tests included blood count, electrolytes and coagulation monitoring, and were unremarkable except for mild anemia (hemoglobin 9.9 g/dL). Contrast CTs of the abdomen and pelvis with PO/IV contrast showed marked gastric distension with luminal narrowing at the level of the duodenal bulb. Small and large bowel appeared normal in caliber and neither obstructions nor wall thickenings could be found. Accordingly, an esophagogastroduodenoscopy was performed showing a non-bleeding, cratered ulcer with a clean ulcer base (Forrest III) in the duodenal bulb. The lesion was 12 mm in largest dimension and surrounded by edema and erythema, resulting in a complete luminal obstruction. Upon gastric decompression with a nasogastric tube and PPI treatment, the patient recovered quickly and was discharged after four days. DISCUSSION: Due to an increase in PPI administration and H. pylori eradication in the last decades, peptic ulcers are nowadays treated early on, and gastric outlet obstruction has become a rare complication of peptic ulcer disease. In this case, we report on a 62-year-old patient who developed an obstructive peptic ulcer following extensive hip surgery and anticoagulation with aspirin and apixaban. We hereby want to highlight the importance of a timely PPI prophylaxis for peptic ulcer disease in severely ill patients with chronic NSAID intake. Conservative measures can moreover suffice to resolve the issue.

Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) — Study section “Digestive Diseases in Primary Care”

The introduction of proton pump inhibitors (PPIs) into clinical practice about thirty years ago has greatly improved our therapeutic approach to acid-related diseases for their well-recognized efficacy and safety.Despite the well-defined indications, however, the use of PPIs continues to grow every year in both western and eastern countries and this phenomenon poses serious queries that include the onset of potential adverse effects and the increase in health care costs. The major reason explaining this worrying market expansion is the inappropriate use of PPIs. In order to re-establish a correct use of these effective drugs in daily clinical practice, the Italian Society of Gastroenterology (SIGE), nominated a panel of experts who reviewed the available clinical literature and produced a series of updated position statements on the use of PPIs in clinical practice.

The appropriate use of proton-pump inhibitors.

The introduction of proton-pump inhibitors (PPIs) into clinical practice since about thirty years has greatly improved our therapeutic approach to acid-related diseases for their well recognized efficacy and safety. Accordingly, the role of surgery has been enormously reduced in this field. The main indications for PPI use are universally acknowledged by many scientific societies and are the following: treatment of gastroesophageal reflux disease in its various forms and complications, eradication of H. pylori infection in combination with two or more antibiotics, therapy of H. pylori-negative peptic ulcers, healing and prevention of NSAID-associated gastric ulcers, co-therapy with endoscopic procedures to control upper digestive bleeding and medical treatment of Zollinger-Ellison Syndrome. Despite the above well-defined indications, however, the use of PPIs continues to grow every year in both Western and Eastern countries and this phenomenon poses serious queries about the appropriate prescription of these drugs worldwide. In fact, the endless expansion of PPI market has created important problems for many regulatory authorities for two relevant features: the progressive and irreversible increase of the costs of therapy with this class of drugs and the greater potential harms for the patients. So, there is the need for a reappraisal of PPI correct indications for both general practitioners and various specialists in order to re-establish a correct use of these effective drugs in daily clinical practice, according to the best evidence-based guidelines.

The Use of Proton Pump Inhibitors and Prescription Pattern by Practicing Physicians at an Academic Hospital

The introduction of proton pump inhibitors has revolutionized the management of acid-related gastrointestinal disorders. Physicians use different regimen when prescribing proton pump inhibitors. In this study we aim to determine the prevalence and pattern of proton pump inhibitors prescription among practicing physicians at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. A cross-sectional study was performed at different levels of doctors ranging from consultants to house officers from March-May 2014. The study included 85 doctors. The prevalence of proton pump inhibitors prescription was 57.65%. Most of the respondents are internal medicine physicians with 58.62% (29 physicians) of them prescribing proton pump inhibitors. As well, half of the surgeons (24) were prescribing proton pump inhibitors. 54.17% of house officers who participated were prescribing proton pump inhibitors. Omeprazole at a dose of 20 mg is the most commonly prescribed by 49.41%, followed by the dose 40 mg prescribed by 41.18%. The rate of prescription for proton pump inhibitors at King Abdulaziz University Hospital with different specialties and levels is comparable to the practice worldwide. It’s noted that house officers are prescribing proton pump inhibitors; they will need to be educated about the use, dosage, and side effects of proton pump inhibitors.

Inhibiteurs de la pompe à protons et rein

Assumed for a long time to be very well tolerated, proton pump inhibitors (PPIs) are widely prescribed for inpatients and outpatients; often beyond their validated indications. Nevertheless, many very varied side effects (pneumopathy, ischemic heart disease, dementia) have been associated with the PPIs during the last decade. Renal toxicity is mainly the occurrence of acute interstitial nephritis (AIN), related to a drug-class effect, involving cellular immunity. AINs, which occur especially in elderly patients, can be difficult to diagnose, with frequently isolated acute kidney injury, appearing with variable delay after the introduction of PPIs. Although sensitive to steroid therapy, patients frequently have an incomplete recovery of the kidney function. Very recently, the risk of chronic kidney disease (CKD) and the risk of progression of CKD among PPIs users have been well demonstrated in several large independent epidemiological studies. It is a low, but a significant side effect because of the millions of PPI prescriptions. Although further studies are needed to investigate the pathophysiological mechanisms leading the use of PPI to CKD, it is appropriate for the physicians to limit PPIs to their correct indications and to monitor renal function during these treatments.

Presence of Fundic Gland Polyps in Patients Undergoing Upper Gastrointestinal Endoscopy: Incidence and the Relation with the Use of Proton Pump Inhibitors

The introduction of Proton Pump Inhibitors (PPI’s) was an important breakthrough in the treatment of reflux disease. Shortly after the introduction it was speculated that these drugs would lead to chronic hypergastrinemia finally resulting in the development of gastric carcinoid tumors. Fortunately, this assumption appeared to be incorrect.

Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience

Background: The aim of this study was to analyze the admissions and the management of peptic ulcer disease (PUD) in a tertiary care surgical center. Methods: We evaluated the medical records of all patients admitted to the University Hospital of Tübingen, Germany, for treatment of PUD during 1989-2008. Patients were included into the study if the diagnosis was verified endoscopically or surgically. Annual number of admissions, length of hospitalization, mortality rate, age, rate of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitor (PPI) medication, rate of Helicobacter pylori infection, and complications of PUD and surgery performed were recorded. Data were analyzed by descriptive analyses, Pearson's chi-square test, and regression analysis. Results: This study included 614 admissions. The number of annual admissions (31 ± 12), the length of hospitalization (9 ± 3 days), and the mortality rate (5 ± 4% per year) remained constant, whereas the age increased (1989: 52 ± 14 years vs. 2008: 67 ± 16 years). The rates of patients with H. pylori infection (47 ± 28% per year), NSAIDs treatment (29 ± 15% per year), and PPI treatment (31 ± 27% per year) remained constant. The most frequent PUD complication was hemorrhage (42 ± 16% per year), followed by perforation (9 ± 8% per year). During 1999-2008, more hemorrhages (125 vs. 121; p < 0.05) and perforations (40 vs. 21; p < 0.05) were registered than during 1989-1998. The rate of emergency surgery increased from 70% during 1989-1998 to 87% during 1999-2008. In contrast, elective surgery decreased from 21% during 1989-1998 to 7% during 1999-2008. Ulcer excision and oversewing was the most frequent surgical procedure performed (59%), with decreasing rates of acid-reducing surgery. Conclusion: Despite recent advances in PUD management, ulcer hemorrhage and perforation remain a significant health burden and a surgical disease.

Changing patterns in the surgical treatment of perforated duodenal ulcer - single centre experience.

IntroductionAlthough the surgical treatment of patients with perforated duodenal ulcer is the method of choice, the introduction of effective pharmacotherapy has changed the surgical strategy. Nowadays less extensive procedures are chosen more frequently. The introduction of laparoscopic procedures had a significant impact on treatment results.AimTo present our experience in the treatment of perforated duodenal ulcer in two periods, by comparing open radical anti-ulcer procedures with laparoscopic ulcer repair.Material and methodsThe analysis covered patients operated on for perforated duodenal ulcer. Two groups of patients were compared. Group 1 included 245 patients operated on in the period 1980–1994 with a traditional method (pyloroplasty + vagotomy) before introduction of proton pump inhibitors (PPI). Group 2 included 106 patients treated in the period 2000–2014 with the laparoscopic technique supplemented with PPI therapy. Groups were compared in terms of patients’ demographic structure, operative time, complication rate and mortality.ResultsThe mean operative time in group 1 was shorter than in group 2 (p < 0.0001). Complications were noted in 57 (23.3%) patients in group 1 and 14 (13.5%) patients in group 2 (p = 0.0312). Reoperation was necessary in 13 (5.3%) cases in group 1 and in 5 cases in group 2 (p = 0.8179). The mortality rate in group 1 was significantly higher than in group 2 (10.2% vs. 2.8%, p = 0.0192). In group 1, median length of hospital stay was 9 days and differed significantly from group 2 (6 days, p < 0.0001).ConclusionsWithin the last 30 years, significant changes in treatment of perforated peptic ulcer (PPU) have occurred, mainly related to abandoning routine radical anti-ulcer procedures and replacing the open technique with minimally invasive surgery. Thus it was possible to improve treatment results by reducing complication and mortality rates, and shortening the length of hospital stay. Although the laparoscopic operation is longer, it improves outcomes. In the authors’ opinion, in each patient with suspected peptic ulcer perforation, laparoscopy should be the method of choice.

75-Year-Old Man With Abdominal Pain and Reflux

75-Year-Old Man With Abdominal Pain and Reflux